Chief Operating Officer Of Dyne Therapeutics Sold 71% Of Their Shares

Some Dyne Therapeutics, Inc. (NASDAQ:DYN) shareholders may be a little concerned to see that the Chief Operating Officer, Susanna High, recently sold a substantial US$725k worth of stock at a price of US$26.67 per share. Probably the most concerning element of the whole transaction is that the disposal amounted to 71% of their entire holding.

Check out our latest analysis for Dyne Therapeutics

The Last 12 Months Of Insider Transactions At Dyne Therapeutics

Notably, that recent sale by Susanna High is the biggest insider sale of Dyne Therapeutics shares that we've seen in the last year. So what is clear is that an insider saw fit to sell at around the current price of US$26.68. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

Dyne Therapeutics insiders didn't buy any shares over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data indicates that Dyne Therapeutics insiders own about US$7.3m worth of shares (which is 0.3% of the company). Whilst better than nothing, we're not overly impressed by these holdings.

So What Do The Dyne Therapeutics Insider Transactions Indicate?

Insiders haven't bought Dyne Therapeutics stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we'd only buy after very careful consideration. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Dyne Therapeutics. Our analysis shows 5 warning signs for Dyne Therapeutics (1 can't be ignored!) and we strongly recommend you look at them before investing.

Of course Dyne Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.